This trial will assess whether taking B. coagulans Unique IS2 improves bowel movement frequency, quality, and related symptoms and quality of life in adults with irregular bowel movements.
0 Primary · 3 Secondary · Reporting Duration: Change from 7 day average prior to baseline to week 1, 2, 3 and 4 average scores. An increase from baseline stool frequency in the B. coagulans group at weeks 1,2,3,4 which is significantly better than the change in the placebo group, is desirable.
Experimental Treatment
Non-Treatment Group
144 Total Participants · 2 Treatment Groups
Primary Treatment: Capsule · Has Placebo Group · N/A
Age 18 - 65 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Ontario | 100.0% |
18 - 65 | 100.0% |
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.: Nutrasource Clinical Trial Site | 100.0% |
Met criteria | 100.0% |